Free Trial

Lexaria Bioscience (LEXX) Competitors

Lexaria Bioscience logo
$1.31 -0.04 (-2.96%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$1.31 0.00 (0.00%)
As of 09/23/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LEXX vs. ATYR, IRD, ANEB, ORMP, ADAG, IPA, VIRI, CRDL, HOWL, and OVID

Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include aTyr Pharma (ATYR), Opus Genetics (IRD), Anebulo Pharmaceuticals (ANEB), Oramed Pharmaceuticals (ORMP), Adagene (ADAG), ImmunoPrecise Antibodies (IPA), Virios Therapeutics (VIRI), Cardiol Therapeutics (CRDL), Werewolf Therapeutics (HOWL), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry.

Lexaria Bioscience vs. Its Competitors

Lexaria Bioscience (NASDAQ:LEXX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Lexaria Bioscience has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lexaria Bioscience has higher revenue and earnings than aTyr Pharma. Lexaria Bioscience is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$460K55.70-$5.80M-$0.67-1.96
aTyr Pharma$230K421.83-$64.02M-$0.80-1.24

In the previous week, aTyr Pharma had 36 more articles in the media than Lexaria Bioscience. MarketBeat recorded 36 mentions for aTyr Pharma and 0 mentions for Lexaria Bioscience. aTyr Pharma's average media sentiment score of 0.15 beat Lexaria Bioscience's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Lexaria Bioscience Neutral
aTyr Pharma Neutral

aTyr Pharma has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. aTyr Pharma's return on equity of -93.69% beat Lexaria Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Lexaria Bioscience-1,849.19% -157.22% -133.69%
aTyr Pharma N/A -93.69%-68.83%

Lexaria Bioscience presently has a consensus price target of $4.00, indicating a potential upside of 205.34%. aTyr Pharma has a consensus price target of $23.25, indicating a potential upside of 2,248.25%. Given aTyr Pharma's higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Lexaria Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lexaria Bioscience
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
aTyr Pharma
0 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.14

Summary

aTyr Pharma beats Lexaria Bioscience on 10 of the 15 factors compared between the two stocks.

Get Lexaria Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LEXX vs. The Competition

MetricLexaria BioscienceMED IndustryMedical SectorNASDAQ Exchange
Market Cap$26.41M$3.16B$5.76B$10.51B
Dividend YieldN/A2.36%5.53%4.57%
P/E Ratio-1.9621.0476.0626.61
Price / Sales55.70252.06472.8291.51
Price / CashN/A46.3537.4661.85
Price / Book2.739.7813.586.45
Net Income-$5.80M-$52.73M$3.29B$271.57M
7 Day Performance8.26%3.16%1.83%2.61%
1 Month Performance65.24%4.69%4.02%7.28%
1 Year Performance-58.01%16.37%77.05%29.60%

Lexaria Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LEXX
Lexaria Bioscience
3.2659 of 5 stars
$1.31
-3.0%
$4.00
+205.3%
-58.5%$26.41M$460K-1.967Positive News
ATYR
aTyr Pharma
2.5052 of 5 stars
$1.04
-1.4%
$23.25
+2,146.4%
-44.1%$101.42M$230K-1.2953
IRD
Opus Genetics
1.7812 of 5 stars
$1.69
-1.2%
$7.33
+333.9%
N/A$101.25M$10.99M-0.8814
ANEB
Anebulo Pharmaceuticals
1.6904 of 5 stars
$2.48
-0.2%
$5.50
+122.2%
+10.4%$101.06MN/A-9.464
ORMP
Oramed Pharmaceuticals
0.3062 of 5 stars
$2.45
+4.5%
N/A+7.1%$100.08M$1.34M-6.9710
ADAG
Adagene
2.9219 of 5 stars
$2.11
+2.7%
$7.00
+232.5%
-8.9%$99.44M$100K0.00260
IPA
ImmunoPrecise Antibodies
2.6417 of 5 stars
$2.10
+8.5%
$4.00
+90.9%
+226.1%$96.68M$17.59M-3.0880Gap Up
VIRI
Virios Therapeutics
0.2987 of 5 stars
$5.01
+4.1%
$5.00
-0.2%
+2,567.4%$96.48MN/A-18.565News Coverage
CRDL
Cardiol Therapeutics
2.8325 of 5 stars
$1.10
-2.2%
$8.00
+630.6%
-52.6%$94.96MN/A-3.2520News Coverage
Positive News
Analyst Revision
HOWL
Werewolf Therapeutics
3.7278 of 5 stars
$2.05
+11.4%
$8.00
+290.2%
-14.8%$94.84M$1.88M-1.2640Positive News
Gap Up
OVID
Ovid Therapeutics
4.2194 of 5 stars
$1.32
+2.3%
$3.10
+134.8%
+13.5%$93.87M$570K-2.4960

Related Companies and Tools


This page (NASDAQ:LEXX) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners